Parents and Educators: Both Can Help Children Attain Academic Heights

This is a photo of Dr. Cornelius Grove, author of The Drive to Learn and A Mirror for Americans.

Dr. Cornelius Grove, author of The Drive to Learn and A Mirror for Americans

This is a photo of the cover of the book The Drive to Learn.

The Drive to Learn, by Cornelius Grove, addresses the mindset with which our youngsters arrive at school.

This is a photo of the cover of the book A Mirror for Americans.

A Mirror for Americans examines the school side of the learning equation, and concerns itself with preschool through grade 5.

Schools will soon return to normal schedules, and there are steps parents and educators can take now to lay the groundwork for improved learning outcomes.

BROOKLYN, NEW YORK, UNITED STATES, April 29, 2021 /EINPresswire.com/ — Children who arrive at school with an emotional commitment to learn are ideally equipped to excel academically. A second factor in their learning success is the set of values that guides the lessons they’re taught during their most impressionable years (preschool–grade 5). These are among the insights of Dr. Cornelius Grove, who has spent decades exploring the cultural factors that affect children’s performance in classrooms.

Consider Dr. Grove’s 138-page book for parents, The Drive to Learn: What the East Asian Experience Tells Us about Raising Students Who Excel. Here he explores the ways in which East Asian parents instill in their children respect for academic knowledge and receptiveness to the formal learning process. After a seven-chapter explanation of cultural values underlying East Asian parents’ mindset, he offers three chapters revealing their specific supportive practices. It’s an outline for action for American parents who deeply value academic learning.

A Mirror for Americans: What the East Asian Experience Tells Us about Teaching Students Who Excel, is the 148-page companion volume to the above book. Dr. Grove examines the school side of the learning equation. East Asian lower-grade lessons gain the advantage because of their tenacious, narrow, yet multifaceted focus on the day’s topic. He addresses, among other things, how East Asians regard teaching and the reasons for pupils’ math superiority. Choice magazine (June issue) “highly recommends” this book for “general readers through faculty.”

“People who’ve had experience in unfamiliar cultures often remark that they now see their own culture with fresh eyes,” Dr. Grove explains. “It’s as though they’ve looked into a mirror and seen alternative possibilities for themselves. They realize that their usual ways of doing things are not etched in stone; instead, they’re choices. Different choices could be made.”

Although each book effortlessly stands alone, The Drive to Learn and A Mirror for Americans combine to encourage complementary reassessments by parents and lower-grade teachers about the more impactful roles they could be playing in upgrading the academic performance and the eventual college readiness of the youngest Americans.

For more detailed overviews, visit TheDriveToLearn.info and AMirrorForAmericans.info.

Author Cornelius N. Grove holds a Master of Arts in Teaching degree from Johns Hopkins and a Doctor of Education from Columbia. He has had a decades-long fascination with the cultural factors that affect children’s ability to learn in school. At a 2005 conference in Singapore, he spoke about the two instructional styles found around the world. In 2013 he wrote The Aptitude Myth: How an Ancient Belief Came to Undermine Children's Learning Today, a historical study of why most Americans believe that inborn ability determines school performance. For two recently published encyclopedias (2015 and 2017), he wrote entries on “pedagogy across cultures.” And now with A Mirror for Americans and The Drive to Learn, he is revealing the complementary roles home and school play in strengthening children’s academic capabilities.

Trish Stevens
Ascot Media Group, Inc.
+1 832-334-2733
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

Go on the Greatest Adventure of Your Life; a Trip Through Your Own Mind.

A Trip Through Your Own Mind Becomes the Adventure of a Lifetime. by What Is Revealed Through Your Currently Hidden Sub-Conscious self.

NORTH PORT, FLORIDA, UNITED STATES, April 29, 2021 /EINPresswire.com/ — GO ON THE GREATEST ADVENTURE OF A LIFETIME; A TRIP THROUGH THE HUMAN MIND!

It’s a dangerous and exhilarating expedition; pursued by evil false-personalities, irrational
thoughts and MANKIND’S own worst enemy, LACK OF ESSENCE.

Travel through secret thought tunnels and explore regions of the mind, of which Mankind currently has no knowledge; in order, to successfully complete the Quest of a lifetime, that of obtaining TRUE “KNOWLEDGE” OF HUMAN EXISTENCE. Jimar is the guide.

“THE JIMARIAN BIBLE” IS THE TREASURE MAP. HEALTH, LOVE, ROMANCE, SEX, FINANCIAL
SECURITY, POLITICS AND EVERYDAY LIVING TAKE ON DIFFERENT PSYCHOLOGICAL CON-
NOTATIONS AND CONSEQUENCES DEPENDING UPON AN INDIVIDUAL’S CHOICE OF
RELIGION AND PHILOSOPHY.

100 YEARS OF LIVING VS AN INFINITY IN TIME & SPACE. WHAT IS MANKIND’S PLACE IN THE
UNIVERSAL ALL? WHAT IS YOUR PLACE?

FOR A FREE PDF COPY GO TO thejimarianbible.com

jimar
Quest Educational Foundation
info@questef.org


Source: EIN Presswire

NASA Awards Eta Space Contract for Gas Stations in Space

LOXSAT 1 in 500 km SSO

Eta Space Logo

Eta Space to Fly LOXSAT Mission to Demonstrate Cryogenic Fluid Management in Orbit

ROCKLEDGE, FLORIDA, UNITED STATES, April 29, 2021 /EINPresswire.com/ — Eta Space signed a $25M contract on April 27 with NASA’s Space Technology Mission Directorate under the Technology Demonstration Missions (TDM) Program to demonstrate critical Cryogenic Fluid Management (CFM) technologies in low Earth orbit. Headquartered in Rockledge, Florida, Eta Space was the only small business awarded one of NASA's STMD “Tipping Point” contracts for a CFM project within the TDM Program. This contract, along with a separate 2019 Tipping Point award to develop cryogenic propellant depots on the Lunar surface, solidifies Eta Space as the new space industry leader in commercial cryogenic propellant servicing.

“The ability to refuel in space is critical to meeting NASA’s goals of sustainable space exploration,” says Dr. William Notardonato, CEO of Eta Space, “but propellant depots have always had an economic ’chicken and egg’ problem. Rockets and spacecraft aren’t designed to be refueled in space since there are no propellant depots, but neither are depots being built because there are no vehicles that can currently use that capability.” Enter NASA’s Tipping Point program. NASA is developing public/private partnerships to fund critical technologies to the economic tipping point at which point the private sector can then take over.

Eta Space developed the LOXSAT mission as a small, low-cost payload to test a dozen critical cryogenic storage and transfer technologies in orbit. After launch in late 2023, the nine-month LOXSAT 1 mission will fully demonstrate the capability of in-space cryogenic storage and transfer. Anticipating successful mission results, Eta Space will use private funding to develop a truly commercial depot intended to serve multiple customers.

The contract includes funding for the initial design of LOXSAT 2, a full-scale operational depot intended for launch in 2025. LOXSAT 2 will provide liquid oxygen and RP-1 to refuel the upper stages of multiple small launch vehicles. “We are working with several launch providers to develop standardized interfaces, promote orbital refueling into mission profiles, and develop supply and demand projections for this new market,” said Dr. Notardonato. “This capability will then be used to open the inner solar system to exploration by small satellites at reduced costs.”

About Eta Space: Eta Space was founded in 2019 by former NASA and contractor personnel with over 130 years of combined experience in CFM. The company is looking to leverage this experience to develop in-space propellant depots to enable the next phase of commercial space exploration. Eta Space is also actively developing several other cryogenic energy systems, including LOX/LH2 depots in orbit and on the Moon, lunar mobility systems, cryogenic ground support equipment for launch applications, and hydrogen energy systems for Earth applications. https://etaspace.com

William Notardonato, PhD
Eta Space
+1 321-282-3855
info@etaspace.com
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

THE NATIONAL SPACE SOCIETY MOURNS THE PASSING OF MICHAEL COLLINS

A Michael Collins crew protrait taken in 1969. Credit: NASA

The Apollo 11 Astronaut and Air Force General is Fondly Remembered

Mike Collins quietly epitomized the courage and audacity of the human spirit which dares to try, dares to fail, and, therefore, dares to succeed”

— Michelle Hanlon, President of the National Space Society

WASHINGTON, D.C., USA, April 29, 2021 /EINPresswire.com/ — The National Space Society mourns the passing of Michael Collins, announced by his family this morning. Colonel Collins flew in space twice, once aboard Gemini 10 in 1966, and then as the Command Module Pilot aboard the mission of Apollo 11. We celebrate his contributions to spaceflight and to the eventual human settlement of space. Collins was a founding member of the National Space Institute, the NSS’s predecessor organization that later merged with the L5 Society to form the NSS.

Michelle Hanlon, NSS President, said, “The landing of humans on the Moon, and their safe return, is one of the greatest technological achievements of humankind. The fact that no human has ventured back to the Moon since 1972 speaks volumes of the difficulty—emotional, physical, academic, intellectual and technological—it took to get there in the first place.” Hanlon, who is also the co-founder of For All Moonkind, a nonprofit that seeks to protect the Apollo landing sites as universal heritage landmarks, added, “While Mike Collins did not leave his bootprints on the lunar surface, he left an imprint on the heart and soul of all on this Earth and quietly epitomized the courage and audacity of the human spirit which dares to try, dares to fail, and ultimately dares to succeed.”

Anita Gale, the NSS CEO added, "“We have lost another connection to those amazing accomplishments of a half-century ago. Collins handled the fame and attention of Apollo with humility, dignity, and grace. We will always remember and respect him.”

Collins was part of NASA’s third astronaut group of 1963, and by 1966 had flown on Gemini 10, conducting two successful spacewalks—only the third astronaut to attempt the task. He then flew as the Command Module Pilot on Apollo 11, orbiting the Moon alone as crewmates Neil Armstrong and Buzz Aldrin explored the lunar surface. While over the far side of the Moon during these many orbits, he was the first person in history to be truly alone. As he wrote in his widely-praised autobiography Carrying the Fire, “I am alone now, truly alone, and absolutely isolated from any known life. I am it. If a count were taken, the score would be three billion plus two over on the other side of the moon, and one plus God knows what on this side.”

Upon returning from the Moon, the Apollo 11 crew began months of public relations touring. Soon thereafter, Collins retired from NASA, working briefly with the U.S. State Department, then becoming the Director of the Smithsonian’s National Air & Space Museum.

“Major General Collins was a truly remarkable person and a gifted pilot, “said Karlton Johnson, the Chairman of the Board of Governors for the NSS and himself a retired Air Force colonel. “He was the epitome of the greatest generation, and his quiet courage as a test pilot and astronaut is to be respected. He was a credit to the Air Force, to his nation, and, simply put, one of the best.”

Rod Pyle, Editor-in-Chief of the NSS’s signature magazine Ad Astra, elaborated: “Mike was widely known as 'the approachable astronaut.' While he could be somewhat shy, he was kind and incredibly generous with his time and celebrity. A true raconteur, he was as likely to be discussing watercolor painting—at which he excelled—or fine wines, as his personal achievements. He was also a very gifted writer, penning some of the most engaging accounts of the Apollo program ever written, and which have sold millions of copies.”

Collins’ family released a brief statement after his passing: “We regret to share that our beloved father and grandfather passed away today, after a valiant battle with cancer. He spent his final days peacefully, with his family by his side. Mike always faced the challenges of life with grace and humility, and faced this, his final challenge, in the same way. We will miss him terribly. Yet we also know how lucky Mike felt to have lived the life he did. We will honor his wish for us to celebrate, not mourn, that life. Please join us in fondly and joyfully remembering his sharp wit, his quiet sense of purpose, and his wise perspective, gained both from looking back at Earth from the vantage of space and gazing across calm waters from the deck of his fishing boat.”

The NSS wishes his family all the best and joins those asking that their privacy be respected in this reflective time.

The National Space Society was founded in 1987 via a merger of the National Space Institute, founded to promote citizen support for the American space program, and the L5 Society, based on the work of space settlement pioneer Gerard K. O’Neill. The NSS is the preeminent citizen's voice on space exploration, development, and settlement. For more information go to space.nss.org.

Rod Pyle
National Space Society
+1 626-399-4440
email us here


Source: EIN Presswire

DRAGONSKIN™ BODY ARMOR IS BACK WITH A BANG! PLANNED V.I.P. DEMONSTRATION SHOOT

Dragonskin™ Flexible Rifle Defeating Body Armor

Pinnacle Armor® announced today that it is back in business and will be showcasing the Dragonskin™ Flexible Rifle Defeating Body Armor.

Dragonskin™ is the best out there…hands down. It’s better than the Interceptor. It is the state-of-the-art…it is two steps ahead of anything I have ever seen. ”

— Col James G. Magee (USMC, Ret)

TORRANCE, CA, UNITED STATES, April 29, 2021 /EINPresswire.com/ — Pinnacle Armor® announced today that it is back in business and will be showcasing the state-of-the-art extraordinary ballistic performance of one of the latest generations of the Dragonskin™ Flexible Rifle Defeating Body Armor at a Live Demonstration Shoot.

Superior to all other systems, this world-renowned, technologically advanced body armor system is back and has further developed into a system that is even more robust, and capable of defeating all known small-arm rifle threats worldwide.

The Dragonskin™ body armor will demonstrate its’ effectiveness against the following military threats: 5.45x39mm, 5.56x45mm, 7.62x39mm, 7.62x51mm, 7.62x54mm, 7.62x63mm, 7.62x66mm, 7.70x56mm, and 7.92x57mm. The bullet types will be ball, pointed steel and LPS rounds. Two rounds of each of these will be fired into one, truly flexible, level 3, threat defeating system!

Dragonskin™ body armor is available in threat levels 3, 4, and a classified level 5 variant for the military. It defeats all rounds within those categories regardless of where in the world the threat was developed. Dragonskin™ is available in various tactical designs, concealed designs, and neutral and positive buoyant carrier designs. Since the original series of Dragonskin™ body armor, there has never been level 3 or 4 systems capable of taking so many different threat levels and have that many rifle threats defeated in one vest.

“This current variant of Dragonskin™ body armor system is distinctly superior in so many areas of functionality and performance, we look forward to continuing technological breakthroughs in flexible armor that will provide increased levels of protection for our armed forces, law enforcement and first responder personnel”, said Ken Hall, CEO of Pinnacle Armor®.

“Dragonskin™ is the best out there…hands down. It’s better than the Interceptor. It is the state-of-the-art…it is two steps ahead of anything I have ever seen. If you would ask me today, Jim, we are sending you to Iraq tomorrow what would you wear? I would buy Dragonskin™ and I would wear it”, said the Inventor of the Interceptor Body Armor, Col James G. Magee (USMC, Ret).

The Demonstration will be for a limited number of invited and vetted guests, it is not open to the public. Law Enforcement, Military, First Responders, Government, Congressional Members and OGA’s are all encouraged to RSVP. Please go to www.dragonskin.com for additional information, or to reserve your place for this break-out demonstration shoot.

Ken Hall
Pinnacle Armor Company
+1 8554401344
email us here

Dragonskin™ Battlefield To The Streets


Source: EIN Presswire

Canadian Laboratory demonstrates that TrioMed Mask filters more Live Viruses than any other mask by at Least 500%

Box of 50 Triomed Antimicrobial Masks

Box of 50 Triomed Antimicrobial Masks

TrioMed Active Masks Proven to Filter Live Viruses between 500%-3600 % better than N95, FFP2 and Procedure masks

MIRABEL, QUEBEC, CANADA, April 29, 2021 /EINPresswire.com/ — i3 Biomedical inc., the Canadian manufacturer of TrioMed Active Surgical Masks today announces that scientific testing executed by the ISO certified laboratory, GAP EnviroMicroBial Services Ltd. demonstrated that the filtration of live virus by the TrioMed Active Mask was superior by 500% – 3600 % when compared to Respirators and Procedure Masks currently available in North America and Europe.

In use for the last decade and tested against many micro-organisms by numerous external laboratories, the TrioMed Active Mask is scientifically proven to deactivate microbes on its external surface within minutes.

Recipient of the 2020 Gold Medal by Canadian Manufacturing, the TrioMed Active Mask was tested against North American and European Respirators & Masks to specifically measure the filtration efficacy of Live Virus.

“After comparing 30 minutes of live virus filtration of the filter material of respirators (N95 & FFP2), medical masks (ASTM 3 & CE class IIR), procedure masks and the TrioMed Active Mask, the TrioMed mask was shown to be clearly superior, demonstrating enhanced virus filtration efficacy between 500% -3600 % better than all tested respirators and masks. Years of work by the TrioMed Team has again demonstrated scientific craftsmanship and know-how that is unequalled “ said Pierre Jean Messier, Executive Chairman.

For more information on the TrioMed Active face masks, visit www.triomed.com or send an email to triomed@triomed.com

About i3 BioMedical Inc: i3 BioMedical is a Canadian medical device corporation, focused on the development and manufacturing of novel antimicrobial products incorporating the TrioMed Active Technology.

About GAP EnviroMicrobial Services Ltd.: GAP EnviroMicrobial Services Ltd. (GAP), established in 1996, is ISO/IEC 17025:2005 compliant with accreditation by the Canadian Association for Laboratory Accreditation (CALA), CALA accreditation is recognized by almost 60 accrediting bodies in 40 countries around the world.

Pierre Jean Messier
i3 Biomedical Inc.
+1 438-792-6288
triomed@triomed.com
Visit us on social media:
Facebook


Source: EIN Presswire

Un Laboratoire Canadien Démontre que le Masque TrioMed Filtre 500% Plus de Virus Vivants Comparé aux Autres Masques

Boîte de 50 masques anti microbiens Triomed

Boîte de masques anti microbiens Triomed

Les masques TrioMed démontrent une efficacité supérieure au niveau de la filtration des virus de 500% à 3600% par rapport aux masques N95, FFP2 et de procédure

MIRABEL, QUEBEC, CANADA, April 29, 2021 /EINPresswire.com/ — i3 Biomedical inc., le fabricant canadien de masques chirurgicaux actifs TrioMed, annonce aujourd'hui que des tests scientifiques exécutés par le laboratoire certifié ISO, GAP EnviroMicroBial Services Ltd., ont démontré que la filtration des virus vivants par le masque actif TrioMed était supérieure de 500% à 3600% par rapport aux respirateurs et masques de procédure actuellement disponibles en Amérique du Nord et en Europe.

Utilisé depuis une dizaine d'années, le masque actif de TrioMed a été testé par de nombreux laboratoires externes, qui ont scientifiquement prouvé son efficacité pour désactiver divers virus et bactéries sur sa surface externe, et ce en l’espace de quelques minutes.

Récipiendaire de la médaille d'or 2020 par Canadian Manufacturing, le masque actif TrioMed a récemment fait l’objet d’un test visant à mesurer spécifiquement l'efficacité au niveau de la filtration de virus vivants et durant lequel cette dernière à été comparée à d’autres modèles de masques populaires en Europe, au Canada et aux États-Unis.

« Les résultats obtenus au bout de 30 minutes ont révélé que la performance au niveau de la filtration virale de la membrane du masque TrioMed est nettement supérieure à celle des autres masques testés (N95, FFP2, masques chirurgicaux de type IIR et ASTM3, masques de procédure), et ont établi une efficacité de filtration virale améliorée entre 500% et 3600% par rapport aux autres masques testés. Ces résultats sont le fruit de plusieurs années de travail de l'équipe TrioMed et démontrent non seulement l’aboutissement de notre approche scientifique mais également un savoir-faire inégalé dans le domaine de la filtration des virus aérosolisés », a déclaré Pierre Jean Messier, Président Exécutif.

Pour tout complément d'information sur les masques TrioMed Active, veuillez consulter le site www.triomed.com ou envoyer un courriel à l'adresse triomed@triomed.com

À propos d'i3 BioMedical Inc : i3 BioMedical est une société canadienne spécialisée dans les dispositifs médicaux, axée sur le développement et la fabrication de produits antimicrobiens novateurs intégrant la technologie TrioMed Active.

À propos de GAP EnviroMicrobial Services Ltd. : GAP EnviroMicrobial Services Ltd. (GAP), créée en 1996, respecte la norme ISO/CEI 17025:2005 avec l'accréditation de l'Association canadienne pour l'accréditation des laboratoires (CALA), qui est reconnue par près de 60 organismes d'accréditation dans 40 pays à travers le monde.

Pierre Jean Messier
i3 Biomedical Inc.
+1 438-792-6288
triomed@triomed.com


Source: EIN Presswire

Laboratorio Canadiense Demuestra que la Mascarilla Triomed filtra mejor los virus vivos que la competencia por un 500%

MASCARILLA TRIOMED - Caja 50 unidades

MASCARILLA TRIOMED – Caja 50 unidades

MIRABEL, QUEBEC, CANADA, April 29, 2021 /EINPresswire.com/ — i3 Biomedical inc., El Fabricante Canadiense de la Mascarilla Activa Quirurgica Triomed anuncio el día de hoy que pruebas cientificas realizadas por el laboratorio certificado ISO, GAP EnviroMicrobial Services Ltd. Ha demostrado que la filtración a virus vivos de la Mascarilla Quirurgíca Activa Triomed fue superior entre un 500% – 3600 % al ser comparada con respiradores y mascarillas actualmente disponibles en Ámerica del Norte y Europa.

Durante la última década, la mascarilla activa Triomed ha sido probada por numerosos laboratorios externos contra diversos microorganismos, comprobando científicamente que la mascarilla activa TrioMed desactiva los microbios en su superficie externa en minutos.

Ganadora de la medalla de oro 2020 por fabricación canadiense, la máscara activa TrioMed fue probada con respiradores y máscaras norteamericanas y europeas para medir específicamente la eficacia de filtración del virus vivo.

“Después de comparar por 30 minutos de filtración de virus vivos en el material de filtro de los respiradores (N95 y FFP2), máscaras médicas (ASTM 3 y CE clase IIR), máscaras de procedimiento y la máscara activa TrioMed, se demostró que la máscara TrioMed es claramente superior, lo que demuestra una eficacia de filtración de virus entre 500% -3600% superior que todos los respiradores y máscaras probados. Los años de trabajo del equipo de TrioMed han demostrado una vez más una destreza científica y un conocimiento inigualable ”, dijo Pierre Jean Messier, presidente ejecutivo.”

Para obtener más información sobre las máscaras faciales TrioMed Active, visite www.triomed.com o envíe un correo electrónico a triomed@triomed.com
Sobre i3 BioMedical Inc: i3 BioMedical es una empresa canadiense de dispositivos médicos, centrada en el desarrollo y fabricación de nuevos productos que incorporan tecnología activa TrioMed antimicrobiana.

Sobre GAP EnviroMicrobial Services Ltd.: GAP EnviroMicrobial Services Ltd. (GAP), establecida en 1996, cumple con la norma ISO / IEC 17025: 2005 con la acreditación de la Asociación Canadiense de Acreditación de Laboratorios (CALA), la acreditación CALA está reconocida por casi 60 organismos de acreditación en 40 países de todo el mundo.

Pierre Jean Messier
i3 Biomedical Inc.
+1 438-792-6288
triomed@triomed.com


Source: EIN Presswire

Breast Cancer Monoclonal Antibodies Market Trends Include Target And Combination Therapy

Breast Cancer Monoclonal Antibodies Market Report 2021: COVID-19 Growth And Change To 2030

Breast Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030

The Business Research Company’s Breast Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030

LONDON, GREATER LONDON, UK, April 29, 2021 /EINPresswire.com/ — Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

Companies in the breast cancer monoclonal antibodies market are investing in targeted and combination therapy, which has proven to be more effective and less toxic than traditional treatment options. Targeted cancer therapies are drugs or substances that block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Combination therapy uses a treatment method in which a patient is given two or more drugs (or other therapeutic agents) for a single disease. In February 2019, the FDA approved the combination of a MAb trastuzumab with hyaluronidase-oysk for SC administration in HER2-positive early breast cancer wherein hyaluronidase is an enzyme that helps the body to use trastuzumab. In 2020, The American Society of Clinical Oncology published the success of combination therapy of a targeted monoclonal antibody atezolizumab with chemotherapy with improved progression-free survival in patients with triple-negative breast cancer. It resulted in the progression-free survival of 7.2 months for patients receiving the combination therapy, compared with 5.5 months for those who received placebo plus nab-paclitaxel (chemotherapy). Promising results with targeted therapies and combination therapies are expected to raise the focus on these therapies in the breast cancer monoclonal antibodies market.

In March 2019, AstraZeneca, a UK-based global biopharmaceutical company that discovers, develops and commercializes prescription drugs in therapy areas such as oncology, cardiovascular, renal & metabolism and respiratory, entered into a collaboration with Daiichi Sankyo Company with an upfront payment of $1.35 billion. Daiichi Sankyo Company Limited is a Japan-based global pharmaceutical company that creates innovative new and generic medicines and new methods of drug discovery and delivery. The collaboration agreement is about the global development and commercialization of trastuzumab deruxtecan (DS-8201), which is an exclusive antibody-drug conjugate (ADC) and a potential new targeted cancer therapy. Except in Japan (exclusive rights for Daiichi Sankyo), the companies will jointly develop and commercialize trastuzumab deruxtecan.

Other major players in the breast cancer monoclonal antibodies (MAbs) market are Amgen, Mylan, Merck, Novartis, GlaxoSmithKline, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, and Array BioPharma.

Read More On The Global Breast Cancer Monoclonal Antibodies Market Report:
https://www.thebusinessresearchcompany.com/report/breast-cancer-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-change

The global breast cancer monoclonal antibodies market is expected to grow from $12.67 billion in 2020 to $13.76 billion in 2021 at a compound annual growth rate (CAGR) of 8.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The breast cancer MAbs market is expected to reach $18.61 billion in 2025 at a CAGR of 8%.

The global breast cancer monoclonal antibodies market is segmented by product into naked MAbs, conjugated MAbs, by end-user into hospitals, retail pharmacies, and by treatment into chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, hormone therapy.

Breast Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides breast cancer monoclonal antibodies market overview, forecast breast cancer monoclonal antibodies market size and growth for the whole market, breast cancer monoclonal antibodies market segments, and geographies, breast cancer MAbs market trends, breast cancer MAbs market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Breast Cancer Monoclonal Antibodies Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3450&type=smp

Here Is A List Of Similar Reports By The Business Research Company:
Monoclonal Antibodies (MAbs) Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-mabs-global-market-report

Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/cancer-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-change

Breast Cancer Diagnostics Global Market Report 2021: COVID-19 Growth And Change to 2030
https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-market-report

HER2 Inhibitors Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/her2-inhibitors-market-global-report-2020-30-covid-19-growth-and-change

Breast Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+ +44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

High Prevalence Of Vascular Diseases Drives The Vascular Grafts Market

Vascular Grafts Market Report 2021: COVID-19 Growth And Change To 2030

Vascular Grafts Global Market Report 2021: COVID-19 Growth And Change To 2030

The Business Research Company’s Vascular Grafts Global Market Report 2021: COVID-19 Growth And Change To 2030

LONDON, GREATER LONDON, UK, April 29, 2021 /EINPresswire.com/ — Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

The rising prevalence of vascular diseases is driving the growth of the global vascular graft market. According to a study by the National Center for Biotechnology Information in the US, cardiovascular diseases are the leading cause of death in the world and according to the American Heart Association (AHA), the overall prevalence of myocardial infarction in the US was around 7.9 million per year, while the estimated annual incidence of a heart attack in the US is 720,000 new attacks and 335,000 recurrent attacks. According to a study by NHS Inform, a national health service of Scotland, every year around 20,000 coronary bypass grafts are carried out in England. Therefore, the high prevalence of vascular diseases is anticipated to drive the global vascular grafts market.

The vascular graft global market consists of sales of vascular grafts and related services by entities (organizations, sole traders and partnerships) that manufacture vascular grafts that are used to repair the diseased or blocked blood vessel during the surgical procedure called vascular grafting or vascular bypass. Vascular grafting is performed to bypass a partial or complete blockage in an artery by reconnecting the blood vessels. This process will improve the blood flow by redirecting blood from one area of the body to another. Vascular grafts are mainly used in the heart during coronary artery bypass and in legs to treat vascular disease.

Read More On The Global Vascular Grafts Market Report:
https://www.thebusinessresearchcompany.com/report/vascular-grafts-global-market-report-2020-30-covid-19-growth-and-change

The global vascular grafts market size is expected to grow from $2.57 billion in 2020 to $2.78 billion in 2021 at a compound annual growth rate (CAGR) of 8.2%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The vascular graft global market is expected to reach $3.64 billion in 2025 at a CAGR of 7%.

The vascular graft market covered in this report is segmented by product into hemodialysis access graft, endovascular stent graft, peripheral vascular graft, coronary artery by-pass graft; by raw material into polyester grafts, EPTFE, polyurethane grafts, biosynthetic grafts; by application into coronary artery disease, aneurysm, vascular occlusion, renal failure; by end-user into hospitals, ambulatory surgical centers.

Major players in the vascular graft global market are B. Braun, C. R. Bard, Cardinal Health, Cook Medical, Endologix, LeMaitre Vascular, Medtronic Plc, Getinge, Terumo Medical Corporation, and Gore Medical.

Vascular Grafts Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides vascular grafts market overview, forecast vascular grafts market size and growth for the whole market, vascular grafts market segments, and geographies, vascular grafts market trends, vascular grafts market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Vascular Grafts Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3419&type=smp

Here Is A List Of Similar Reports By The Business Research Company:

Peripheral Vascular Devices And Equipment Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/peripheral-vascular-devices-and-equipment-global-market-report

Cardiovascular Surgery Devices And Equipment Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/cardiovascular-surgery-devices-and-equipment-global-market-report

Wearable Blood Pressure Monitors Market – By Product (Upper Arm Blood Pressure Monitor, Wrist Blood Pressure Monitor, Finger Blood Pressure Monitor), And By Region, Opportunities And Strategies – Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/wearable-blood-pressure-monitors-market

Interested to know more about The Business Research Company?

Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire